Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorVasou, Andri
dc.contributor.authorSultanoglu , Nazife
dc.contributor.authorGoodbourn, Stephen
dc.contributor.authorRandall, Richard Edward
dc.contributor.authorKostrikis, Leondios G.
dc.date.accessioned2017-07-18T15:30:08Z
dc.date.available2017-07-18T15:30:08Z
dc.date.issued2017-07
dc.identifier.citationVasou , A , Sultanoglu , N , Goodbourn , S , Randall , R E & Kostrikis , L G 2017 , ' Targeting pattern recognition receptors (PRR) for vaccine adjuvantation : from synthetic PRR agonists to the potential of Defective Interfering Particles (DIPs) of viruses ' , Viruses , vol. 9 , no. 7 , 186 . https://doi.org/10.3390/v9070186en
dc.identifier.issn1999-4915
dc.identifier.otherPURE: 250496288
dc.identifier.otherPURE UUID: b28b727d-1600-4aa0-a19b-530fe3959c9a
dc.identifier.otherScopus: 85025659074
dc.identifier.otherORCID: /0000-0003-4051-4658/work/54516602
dc.identifier.otherORCID: /0000-0002-9304-6678/work/60427003
dc.identifier.otherWOS: 000406684400028
dc.identifier.urihttps://hdl.handle.net/10023/11249
dc.descriptionThis work was supported by financial support from the University of Cyprus (Grant 8037P-3/311-25020) awarded to L.G.K, and Wellcome Trust Senior Investigator Awards to S.G. and R.R. (101788/Z/13/Z, 101792/Z/13/Z).en
dc.description.abstractModern vaccinology has increasingly focused on non-living vaccines, which are more stable than live-attenuated vaccines but often show limited immunogenicity. Immunostimulatory substances, known as adjuvants, are traditionally used to increase the magnitude of protective adaptive immunity in response to a pathogen-associated antigen. Recently developed adjuvants often include substances that stimulate pattern recognition receptors (PRRs), essential components of innate immunity required for the activation of antigen-presenting cells (APCs), which serve as a bridge between innate and adaptive immunity. Nearly all PRRs are potential targets for adjuvants. Given the recent success of toll-like receptor (TLR) agonists in vaccine development, molecules with similar, but additional, immunostimulatory activity, such as defective interfering particles (DIPs) of viruses, represent attractive candidates for vaccine adjuvants. This review outlines some of the recent advances in vaccine development related to the use of TLR agonists, summarizes the current knowledge regarding DIP immunogenicity, and discusses the potential applications of DIPs in vaccine adjuvantation.
dc.language.isoeng
dc.relation.ispartofVirusesen
dc.rights© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en
dc.subjectDefective interfering particlesen
dc.subjectDefective viral genomesen
dc.subjectInnate immunityen
dc.subjectVaccine adjuvantsen
dc.subjectPattern recognition receptor agonistsen
dc.subjectQH301 Biologyen
dc.subjectQR355 Virologyen
dc.subjectT-NDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccQH301en
dc.subject.lccQR355en
dc.titleTargeting pattern recognition receptors (PRR) for vaccine adjuvantation : from synthetic PRR agonists to the potential of Defective Interfering Particles (DIPs) of virusesen
dc.typeJournal articleen
dc.contributor.sponsorThe Wellcome Trusten
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Biologyen
dc.contributor.institutionUniversity of St Andrews. Biomedical Sciences Research Complexen
dc.identifier.doihttps://doi.org/10.3390/v9070186
dc.description.statusPeer revieweden
dc.identifier.grantnumber101788/Z/13/Zen


This item appears in the following Collection(s)

Show simple item record